🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr. Marina Garassino at #WCLC24 Presidential Plenary presents Normalized Membrane Ratio of TROP2 as a biomarker for datopotamab deruxtecan in TROPION-Lung01 (Dato-DXd vs docetaxel in previously treated NSCLC which previously showed PFS benefit with Dato-DXd.

Day 1 of #AACR25 begins later today in Chicago, with a Grant Writing Workshop at 1:00 PM CT and the launch of the Educational Program at 3:00 PM CT.

Expert talk on ctDNA by Stefania Morganti breast cancer- we need more data on what to do for pts with MRD in the adjuvant setting Stefania Morganti, MD Dana-Farber’s Breast Oncology Center VIRGINIA KAKLAMANI

Ogni anno l’Associazione Americana per la Ricerca sul Cancro bandisce un premio prestigiosissimo per un giovane talento distintosi per scoperte e pubblicazioni. Quest’anno l’ha vinto Sandra Misale, ormai stella del firmamento scientifico mondiale e orgoglio di casa nostra.

Congratulations to the 2025 Cancer Discovery Early Investigator Award recipient Sandra Misale.

Another excellent educational talk about ADC design aspects at #AACR25 by Rafaele Colombo. Linking payload potency & linker stability to clinical observations. Well, it remains complex to deduce generalizable design principles. Understanding payload fate is crucial.

Fecal Microbiota Transplantation (#FMT) has shown promising results in improving immunotherapy efficacy in NSCLC, melanoma, and RCC clinical trials. Excellent plenary presentation by Nicola Segata AACR #AACR25

Regina Reilly AbbVie disclosing dual-targeting STEAP1/PSMA ADC ABBV-969 carrying a permeable TOPi payload. The dual format apparently influencing (at the shown time point) internalization. In vitro/vivo data support the translational rationale for dual targeting. #AACR25 AACR

Intriguing data from Ph1 trial w/ SYS6010, a novel EGFR targeting ADC. Low incidence of EGFR inhibition-specific side effects. High ORR in both TKI-resistant & TKI+chemo-resistant #NSCLC. Further exploration warranted. EGFR Resisters Young Lung Cancer Initiative #AACR25

First clinical data (small patient #) of a PD-L1 x VEGF-A bispecific + TROP2 ADC combo! #AACR25 #ADC

New HER2 Targeted Therapy Alert! 🧬 Zongertinib (BI 1810631) = Game-changer? ✅ 71% ORR ✅ 12.4 mo PFS ✅ Active in brain metastases ✅ No ILD ❌ ✅ EGFR-sparing ➔ Less rash, diarrhea! ⚡ Direct comparison vs trastuzumab deruxtecan! ⚡ Clinical MoA snapshot included! Swipe ➡️

Online now concurrent with the #AACR25 oral presentation by Cancer Discovery Early Career Award Winner Sandra Misale: Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations brnw.ch/21wSh8j

🔥Predictive Biomarkers of Response to (Neo)Adjuvant therapy in Breast Cancer: What’s New? Great educational session with two friends Christos Sotiriou and Theodoros Foukakis Thank you AACR for the invitation Did you miss it? Don’t worry, the virtual meeting is the solution😉 #AACR25

🚨 Breakthrough Device Designation for the first #AI-driven companion diagnostic in #NSCLC! VENTANA TROP2 RxDx Device by Roche uses AI + digital pathology to deliver diagnostic precision beyond manual scoring. Big step forward in #precision oncology. LungCancerRx 🫁💊 OncoAlert

Thrilled to discuss an interesting HER2 TCE bispecific antibody presented by Shanu Modi in this exciting session. Crowded field but bispecifics clearly have promise in breast cancer. ⁦AACR⁩ #AACR2025 ⁦Memorial Sloan Kettering Cancer Center⁩ City of Hope⁩

Based on AstraZeneca’s QCS for TROP2, Roche Diagnostics received FDA Breakthrough Device Designation (BDD) for the VENTANA TROP2 (EPR20043) RxDx assay! Nice spotlight presentation at #AACR25 roche.com/media/releases…

Highlights from the 2025 Cancer Statistics Report: Cancer Deaths: From 1991 to 2022, mortality dropped 34%, preventing 4.5M deaths due to less smoking, early detection, and better treatments. New Cases: 2,041,910 new cases expected in 2025 (~5600/day). Men: 1,053,250; women:

What is the cause of ADC-related ILD? Spoiler: most likely not the antibody target (e.g. not HER2). New data confirms prior observations that T-DXd affects alveolar macrophages (AM) via Fc–FcγR engagement, triggering immune activation and ultimately ILD. aacrjournals.org/cancerres/arti…

🧬Liquid Biopsy Approaches for Cancer ASCO Educational Book ✅Characterization, Residual Disease Detection, and Therapy Monitoring ✅Trials of NSCLC and breast cancer 👉doi.org/10.1200/EDBK-2… OncoAlert Journal of Clinical Oncology #cancer #oncology #MedX

Only 2 weeks to #ESMOBreast25, one of my favorite conferences. Dozens of impactful abstracts to be presented, alongside great educational presentations to put the new data into context. Here’s a personal selection of 10 key presentations to follow during the conference. #bcsm